MacroGenics reports Q2, streamlines model, updates ADC and bispecific pipeline
MacroGenics paired second-quarter results with a completed manufacturing divestiture and fresh pipeline updates, including a Gilead option exercise and ESMO data plans.
MacroGenics reported second-quarter 2026 results alongside several pipeline and corporate updates. MGC026, the company's B7-H3-targeted ADC, hit a milestone as its SCCHN cohort met the pre-specified response threshold to advance into Stage 2, with interim Phase 1 results accepted for a poster at the ESMO 2026 Congress in October.1 Dose escalation in that trial has wrapped up after testing a range from 1 mg/kg to 9 mg/kg given every three weeks, and the company is now studying 7.5 mg/kg Q3W across four tumor cohorts: SCCHN, endometrial cancer, melanoma and soft tissue sarcoma.1
MGC028, targeting ADAM9, remains in dose escalation, with preliminary clinical data expected in late 2026.1 MGC030, the company's newest ADC against an undisclosed target, had its IND cleared by the FDA in the second quarter, ahead of schedule, and a Phase 1 dose escalation study is set to start in the third quarter of 2026.1
On the bispecific side, the Phase 2 LINNET study of lorigerlimab continues, with 20 additional clear cell gynecologic cancer patients being enrolled at 3 mg/kg Q3W and updated results expected in the first half of 2027.1 MacroGenics also nominated MGD032, a next-generation T-cell engager against an undisclosed target, now advancing into IND-enabling studies.1
On August 11, Gilead exercised its option to license a preclinical bispecific program under the companies' 2022 collaboration agreement, triggering a $10.0 million payment to MacroGenics.1
Corporately, MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals and Bora Biologics USA for a base price of $122.5 million, receiving $119.6 million in cash after adjustments, with about 140 former employees moving to Bora and the remaining workforce expected to settle near 140 by year-end.1
Cash, equivalents and marketable securities were $173.3 million as of June 30, 2026, down from $189.9 million at year-end 2025.1 The company said its pro forma cash position of $327 million, plus expected future partner payments, is projected to support its cash runway through 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.